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ORIGINAL RESEARCH

Trends in Cannabis-Related and Opioid-Related
Hospitalization Rates in Maine, 2010-2020
Suzanne McMahon, MPH1, Katherine A. Ahrens, MPH, PhD1
1

Muskie School of Public Service, University of Southern Maine, Portland, ME

Introduction:

Medical marijuana use became legal in the state of Maine in 1999, and recreational adult-use marijuana
became legal in 2016. However, the rates of hospitalization related to marijuana (also known as
cannabis) use have not been studied. We estimated trends in cannabis-related hospitalization rates in
Maine based on rurality and descriptively compared these trends to opioid-related hospitalization rates
during the past decade.

Methods:

We obtained de-identified data of inpatient encounters for Maine residents between 2010 and 2020 from
MaineHealth Data Organization. We then calculated age-standardized rates of cannabis-related and
opioid-related hospitalizations overall and by rural-urban residence using International Classification
of Diseases clinical modification (ICD-CM) diagnosis codes. We used Poisson regression models to
assess linear trends over time, stratified by ICD-9-CM versus ICD-10-CM timeframes.

Results:

Cannabis-related inpatient encounters accounted for 2.3% of all inpatient encounters among Maine
residents between 2010 and 2020 and increased 0.3% per quarter between 2016 and 2020. Rates for
urban residents were higher than rates for rural residents. Opioid-related inpatient encounters among
Maine residents accounted for 3.4% of all inpatient encounters, and rates increased 0.6% per quarter
between 2016 and 2020. Rates were higher among urban versus rural residents.

Discussion:

We found increasing rates of cannabis-related and opioid-related inpatient encounters in Maine spanning
a period that included when recreational adult-use marijuana was legalized, but largely preceded its
retail sales in Maine (October 2020).

Conclusions:

These trends and other public health impacts of increased access to marijuana use in Maine should
continue to be monitored, especially after recreational adult-use marijuana is fully implemented.
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Medical marijuana use is legal in 36 states in
the United States, and 18 states have approved
recreational adult-use marijuana.1 In Maine,
medical marijuana use has been legal since 1999,
and recreational adult-use marijuana has been
legal since 2016, with retail purchase beginning
in October 2020.2,3 Although other areas have
seen increased rates of acute care encounters
related to marijuana use after legalization, rates of
hospitalizations related to marijuana use have not
yet been examined for Maine.4-6
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Maine was ranked fourth in the nation for state-level
prevalence in past-month marijuana use between
2018 and 2019 (17.6%).7 Though more recent
prevalence has not been measured, retail sales
for recreational adult-use marijuana in Maine were
$29.2 million from October 2020 to June 2021, and
for medical marijuana use were $111.6 million in
2019. Revenue for medical marijuana now ranks
third behind the state’s top traditional revenuegenerating products of lobster and potato.8,9 Further,
the number of patients with medical certification to
buy medical marijuana in Maine increased nearly
50% from 2019 to 2020, now standing at 96 046
patients (Maine’s total population is 1.344 million).10
Although marijuana use is more prevalent in urban
areas across the United States, the fastest growing
1
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cohort of marijuana users are those who are nontobacco smokers living in rural areas.11 Maine is the
state with the largest share of rural residents in the
country (61%),12 which, together with a now robust
medical and recreational adult-use marijuana
market, may translate to steep increases in the
prevalence of marijuana use.
Increased prevalence of marijuana use in Maine
through medical use and recreational adult-use
could have adverse consequences for public
health.13 Marijuana (also known as cannabis) is
still classified as a Schedule I substance under the
Controlled Substances Act, indicating a potential
for abuse.14 Most marijuana products are not
approved by the Food and Drug Administration
and have not been reviewed and studied for
safety, effectiveness, and quality.15 Findings from a
widely-cited report from the National Academies of
Sciences, Engineering, and Medicine described the
positive and negative health effects of marijuana
use. The report included studies linking marijuana
use to an increased risk of motor-vehicle accidents
and marijuana poisoning, as well as low birth weight
among infants exposed in utero.16-18 The report also
stated that marijuana use may harm memory and
learning abilities, and frequent marijuana use may
lead to the development of schizophrenia and other
psychoses.
Regarding the public health effects of marijuana
legalization, findings are mixed. One study found
legalization of recreational adult-use marijuana
had no effect on the overall number of inpatient
encounters, length of stay, or cost.4 The same study
found that after recreational adult-use marijuana
was legalized, inpatient encounters for cannabis
abuse, motor-vehicle accidents, alcohol abuse,
and overdose injury were higher, whereas chronic
pain-related inpatient encounters were lower. Other
studies found that cannabis-related hospitalizations
doubled after recreational adult-use marijuana
was legalized.5,19 Some evidence suggests that
marijuana legalization may reduce opioid-related
hospitalizations and deaths, under the hypothesis
that opioid users may shift to using marijuana to
address their chronic pain.20-22 However, others
found that marijuana legalization was not associated
with reduced rates of death due to opioid overdose,
and may have actually increased these rates over
time.23,24
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With recreational adult-use marijuana now legal
in Maine, and medical marijuana now accounting
for one of the top crop sales in the state, analyses
of the health impacts of increased access to
marijuana are warranted. Our objectives were to (1)
estimate trends in cannabis-related hospitalization
rates in Maine overall and based on rurality, and
(2) descriptively compare estimated trends of
cannabis-related hospitalization rates to opioidrelated hospitalization rates. Our findings may also
be relevant to other states in the United States,
as more than one-third of all states have legalized
recreational adult-use marijuana.25

METHODS
Data source
We used inpatient encounter data from the Maine
Health Data Organization (MHDO) as reported by
Maine hospitals, including private and psychiatric
hospitals. The MHDO is a state agency whose
primary purpose is to collect health care information
and maintain health databases for public use,
including research and policy.26 This project was
deemed non-human subjects research by the
University of Southern Maine’s Institutional Review
Board. Per our data-use agreement with MHDO,
the presentation of results based on counts of 10 or
fewer were suppressed.
Study population
The study population used for this analysis
included all inpatient encounters (hereafter
“encounters”) reported to the MHDO from 2010
to 2020. Encounters included those originating
from the emergency department, excluding treatand-release visits. Any encounters for non-Maine
residents were excluded from the analysis.
Measures
To define rural vs urban areas of residence for
patients in Maine, the US postal code of each
encounter was linked to its corresponding ruralurban commuting area codes (RUCA). A RUCA
code classifies census tracts using population
density, urbanization, and daily commuting
information. Census tracts have been cross-walked
to zip codes.27 The most current set of RUCA codes
are based on data from the 2010 US decennial
census. We used RUCA level 2 codes 1 and 1.1
to define urban Maine and all other RUCA level 2
codes to define rural Maine.28
2
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Diagnoses (principal, admitting, and other)
were recorded for each encounter and coded
by hospitals in Maine using the International
Classification of Diseases, Clinical Modification
(ICD-CM) codes.29 On October 1, 2015, the US
transitioned from ICD-9 clinical modification (ICD9-CM) to ICD-10-CM. As encounters in our study
included both revisions, ICD-9-CM and ICD-10CM codes were used to identify encounters as
cannabis-related and/or opioid-related. Cannabisrelated encounters included ICD-CM codes (in any
position) for cannabis use, abuse, dependence,
and poisoning, consistent with a previous study of
cannabis-related hospitalizations.30 Opioid-related
use included ICD-CM codes (in any position) for
opioid use, abuse, dependence, and poisoning.
These codes were consistent with a definition
used by the Agency for Healthcare Research and
Quality, except we excluded long-term use of opioid
analgesics (Appendix A)..31 External causes of
injury and poisoning codes, which are secondary
codes used to provide additional context for injury
classification, were not used in this analysis.
Delivery-related
hospitalizations
(neonatal,
maternal) were identified using codes from the
Centers for Medicare and Medicaid Services
Medicare Severity Diagnosis Related Groups
(Appendix A).32
Statistical analysis
Analyses were performed using SAS for Windows
Version 9.4 (Cary, NC, USA). We first tabulated
inpatient encounters by year, age group (< 5 years,
10-year intervals up to 84 years, and 85 ≤ years),
sex, rurality of residence, and delivery-related
hospitalization type. We calculated age-specific
rates per 100 000 population by dividing the number
of encounters for each age group by population
estimates for that age group from the US Census
Bureau.33 We then weighted the age-specific rates
to the age distribution of the US population in 2000
through age standardization. This approach allows
the rates in Maine to be compared to other states,
even if the age distributions of the populations
vary.34
We used Poisson regression models to calculate
age-standardized rates of cannabis-related
and opioid-related hospitalizations, and 95%
confidence intervals by quarter. We also used
these models to estimate linear trends (on the log
scale) in hospitalization rates across the quarters.
Published by MaineHealth Knowledge Connection, 2022

We separately estimated trends before and after
the switch to ICD-10-CM because of discontinuities
noted in measuring opioid-related encounters
across the transition.35 We stratified models by
rurality of residence, and we assessed differences
in linear trends between rural and urban residents
using cross-product terms.
COVID-19-related hospitalizations
Encounters with a diagnosis code for COVID-19
(which went into effect in quarter 2 of 2020)
were included in our inpatient dataset.36 As this
population comprised only 1.2% of the total inpatient
encounters in 2020 (n = 1474), we chose to include
these hospitalizations in our analysis, even though
they represented a novel diagnosis.

RESULTS
Cannabis-related and opioid-related inpatient
encounters are tabulated in Table 1 by year,
age, sex, rurality of residence, and delivery
hospitalization type. Across all study years (2010
through 2020), 35 797 cannabis-related encounters
represented 2.3% of all encounters. The number of
opioid-related encounters for the same period was
52 751, which represented 3.4% of all encounters.
The highest proportion of cannabis-related
encounters was found for age groups 15 to 24 years
(10.9% of total encounters) and 25 to 34 years
(6.6% of total encounters). The age groups with the
highest proportion of opioid-related encounters were
older: age groups 25-34 and 35-44, representing
11.1% and 10.1% of total encounters, respectively.
The proportion of cannabis-related encounters was
higher for males than females (2.9% males vs 1.8%
females), as was the proportion of opioid-related
encounters (3.6% males vs 3.2% females).
The proportion of cannabis-related encounters was
higher among urban residents than rural residents
(2.8% urban vs 2.1% rural), as was the proportion
of opioid-related encounters (4.1% urban vs 3.1%
rural).
The proportion of cannabis-related encounters
for neonatal hospitalizations were suppressed
as hospitalization counts were less than 10, and
the proportion of opioid-related encounters was
0.02% (substance use, abuse, and disorders
are not possible among newborns, so these
reports are likely an error). For maternal delivery
hospitalizations, the proportion of cannabis-related
3
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Table 1. Cannabis-Related and Opioid-Related Inpatient Encounters
All Encounters,
No.

Cannabis-related,
No. (%)

Opioid-related,
No. (%)

1 551 282

35 797 (2.3)

52 751 (3.4)

2010

151 743

1960 (1.3)

4115 (2.7)

2011

151 482

2283 (1.5)

4248 (2.8)

2012

147 377

2341 (1.6)

4402 (3.0)

2013

141 017

2440 (1.7)

3998 (2.8)

2014

141 366

2593 (1.8)

3887 (2.7)

2015

140 866

3053 (2.2)

4097 (2.9)

2016

140 438

4196 (3.0)

5457 (3.9)

2017

141 203

4168 (3.0)

5289 (3.7)

2018

137 355

4024 (2.9)

5518 (4.0)

2019

137 503

4333 (3.2)

5755 (4.2)

2020

120 932

4406 (3.6)

5985 (4.9)

<5

152 727

22 (0.0)

108 (0.1)

5-14

23 857

464 (1.9)

81 (0.3)

15-24

84 319

9158 (10.9)

5225 (6.2)

25-34

143 953

9457 (6.6)

15 961 (11.1)

35-44

108 238

6183 (5.7)

10 967 (10.1)

45-54

155 273

5624 (3.6)

8493 (5.5)

55-64

228 576

3619 (1.6)

6235 (2.7)

65-74

267 560

1142 (0.4)

3320 (1.2)

75-84

237 772

113 (0.05)

1537 (0.6)

85≤

149 003

15 (0.01)

824 (0.6)

Female

848 801

15 462 (1.8)

27 338 (3.2)

Male

702 422

20 331 (2.9)

25 411 (3.6)

Urban

495 493

13 646 (2.8)

20 503 (4.1)

Rural

1 055 349

22 126 (2.1)

32 212 (3.1)

Neonatal

135 068

suppressed§

22 (0.02)

Maternal

126 471

3927 (3.1)

4375 (3.5)

Total
Year

Age, y*

Sex†

Rurality of residence‡

Delivery-related
hospitalizations

*Missing data for age: all encounters (n = 4), cannabis-related (n = 0), opioid-related (n = 0).
†Missing data for sex: all encounters (n = 59), cannabis-related (n = 4), opioid-related (n = 2).
‡Missing data for rurality of residence: all encounters (n = 440), cannabis-related (n = 25), opioid-related (n = 36).
§Presentation of results based on counts of 10 or fewer were suppressed per data use agreement.
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encounters was 3.1%, and the proportion of opioidrelated encounters was 3.5%.
Age-standardized rates of annual hospitalization for
cannabis-related encounters per 100 000 population
are shown in Table 2. Over the past 5 years (after the
switch from ICD-9-CM to ICD-10-CM), cannabisrelated hospitalization rates in Maine were lowest
in 2018 (327.2 per 100 000) and highest in 2020
(354.1 per 100 000). Age-standardized rates of
cannabis-related hospitalizations were lower
among rural residents. For example, in 2020, the
rate among rural residents was 331.7 per 100 000
and among urban residents was 403.8 per 100 000.
Age-standardized rates of hospitalization per
100 000 population for opioid-related encounters
are shown in Table 2. Since the ICD-10-CM switch,
opioid-related hospitalization rates in Maine were
lowest in 2017 (402.3 per 100 000) and highest
in 2020 (454.8 per 100 000). In 2020, the opioidrelated hospitalization rate among rural residents
was lower than among urban residents (434.5 per
100 000 rural vs 503.9 per 100 000 urban).
Age-standardized rates of cannabis-related
hospitalizations per 100 000 population increased
from quarter 1 of 2010 through quarter 3 of 2015
(from 41.6 to 60.7 per 100 000; slope = 1.6% per
quarter, P < .001; Figure 1A). After the transition to
ICD-10-CM, we found a more attenuated increase
for cannabis-related hospitalization rates (from 80.7
to 83.2 per 100 000; slope = 0.3%, P = .004; Figure
1A). Rates among urban residents were 46.7 in
quarter 1 of 2010 and increased to 64.3 in quarter 3
of 2015 (slope = 1.2%, P < .001; Figure 1B). These
rates continued to increase from quarter 4 of 2015
through quarter 4 of 2020 (from 81.0 to 94.7 per
100 000, slope = 0.5%, P = .003; Figure 1B). Among
rural residents, rates increased from 39.2 in quarter
1 of 2010 to 59.2 in quarter 3 of 2015 (slope =
1.9%, P < .001; Figure 1C). From quarter 4 of 2015
onwards, rates among rural residents remained
flat (from 81.1 to 77.7 per 100 000, slope = 0.2%,
P =.154; Figure 1C). The slope was significantly
greater among rural residents than urban residents
before the ICD-10-CM transition (P < .01) but was
not significantly different after the transition (P =
.118).
Age-standardized
rates
of
opioid-related
hospitalizations per 100 000 population decreased
from quarter 1 of 2010 through quarter 3 of 2015
Published by MaineHealth Knowledge Connection, 2022

(from 81.5 to 76.3 per 100 000; slope = -0.5%, P <
.001; Figure 2A). After the transition to ICD-10-CM,
rates increased (from 104.3 to 115.4 per 100 000;
slope = 0.6%, P < .001; Figure 2A). Rates among
urban residents decreased from 103.2 in quarter 1
of 2010 to 81.6 in quarter 3 of 2015 (slope = -0.8%,
P < .001; Figure 2B). After the transition to ICD-10CM, the opioid rates among urban residents rose
from quarter 4 of 2015 through quarter 4 of 2020
(from 111.0 to 135.5 per 100 000; slope = 0.9%, P
< .001; Figure 2B). Among rural residents, rates
stayed flat from 70.2 in quarter 1 of 2010 to 73.7 in
quarter 3 of 2015 (slope = -0.2%, P = .094; Figure
2C). From quarter 4 of 2015 onwards, rates among
rural residents showed a slight increase (from 102.0
to 106.0 per 100 000; slope = 0.5%, P < .001; Figure
2C). Compared to rural residents, slopes were
significantly lower among urban residents before
the ICD-10-CM transition (P < .01) and higher after
the transition (P = .026).

DISCUSSION
Cannabis-related inpatient encounters among
Maine residents accounted for 2.3% of all inpatient
encounters in Maine between 2010 and 2020. Agestandardized rates of hospitalization for Maine
increased approximately 0.3% per quarter during
the past 5 years. Whereas rates among urban
residents increased approximately 0.5% per quarter
during the same period, rates among rural residents
showed no significant increase. Rates were higher
among urban vs rural residents for all study years.
Opioid-related inpatient encounters among
Maine residents were slightly more common than
cannabis-related inpatient encounters, accounting
for 3.4% of all inpatient encounters. During the
past 5 years, opioid-related hospitalization rate
increases approximately 0.6% per quarter, with
greater rates among urban vs rural residents. As
with cannabis-related hospitalizations, opioidrelated hospitalization rates were higher among
urban residents than rural residents for all study
years.
The proportions of hospitalizations related to
cannabis and opioid use in Maine were higher
than reported for other states, before and after the
ICD-CM transition. In the US National Inpatient
Sample data from 1998 to 2014, the proportion of
hospitalizations with ICD-9-CM diagnosis codes
for cannabis abuse or dependence (excluding inremission codes) increased from 0.4% to 1.6%
5
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Table 2. Age-Standardized* Rates of Cannabis-Related and Opioid-Related Hospitalizations Per 100 000 Population
Cannabis-related
Year

Maine

2010

Opioid-related
Maine - Rural

Maine - Urban

Maine

Maine - Rural

Maine - Urban

Rate

SE

Rate

SE

Rate

SE

Rate

SE

Rate

SE

Rate

SE

158.6

3.5

143.9

4.0

188.9

6.7

327.1

5.0

285.4

5.6

411.3

9.9

2011

186.5

3.7

170.5

4.3

221.6

7.3

343.5

5.1

301.7

5.8

430.2

10.1

2012

192.0

3.8

173.2

4.4

231.8

7.4

360.3

5.2

308.2

5.8

464.2

10.5

2013

198.6

3.9

180.5

4.5

236.7

7.5

329.5

5.0

288.2

5.6

411.1

9.9

213.0

4.0

203.9

4.7

234.4

7.4

318.0

4.9

283.5

5.6

390.2

9.6

251.5

4.3

241.1

5.2

274.2

8.0

328.7

5.0

313.0

5.9

364.2

9.3

336.8

5.0

320.1

5.9

373.3

9.4

413.6

5.6

403.2

6.7

438.1

10.2

2014
2015
2016

†

2017

335.4

5.0

323.7

6.0

362.9

9.2

402.3

5.5

377.2

6.5

454.2

10.3

2018

327.2

5.0

328.3

6.0

330.5

8.8

421.2

5.6

392.5

6.6

482.3

10.6

2019

345.8

5.1

335.2

6.1

373.2

9.3

437.6

5.7

412.7

6.7

498.3

10.8

2020

354.1

5.1

331.7

6.0

403.8

9.7

454.8

5.8

434.5

6.9

503.9

10.9

Abbreviations: SE, standard error.
*Age-standardized to the US population in 2000.
†Quarter 1 to quarter 3 of 2015 coded with ICD-9; quarter 4 of 2015 coded with ICD-10.
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Figure 1. Age-Standardized Rates of Cannabis-Related Hospitalizations Per
100 000 Population. Slope represents the percent increase per quarter (Q).
1.
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1.

Figure 2. Age-Standardized Rates of Opioid-Related Hospitalizations Per
100 000 Population. Slope represents the percent increase per quarter (Q).
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during the study period.37 For comparison, we
estimated 1.8% of hospitalizations were related to
cannabis use in 2014. Few studies have estimated
cannabis-related hospitalizations using ICD-10CM codes. However, in Mississippi (where medical
marijuana was legalized in 2020) diagnosis codes
in the top 2 positions were found for 2.8% of
hospitalizations in 2019.38 For comparison, we
found 3.2% of hospitalizations were cannabisrelated (we identified these hospitalizations using
codes in any position). Estimates from other states
for comparison are lacking.
In our study, we found a doubling of age-standardized
rates of cannabis-related hospitalizations in Maine
from 158.6 in 2010 to 354.1 in 2020. Some of this
increase seemed due to the transition from ICD-9CM to ICD-10-CM. For example, rates per 100 000
population were 60.7 in quarter 3 vs 80.7 in quarter
4 of 2015. However, we found significant increases
in rates before and after the ICD-CM transition. Our
study period included hospitalizations after medical
marijuana use was legalized (1999) and after
recreational adult-use marijuana was legalized
(November 2016), but largely before retail purchase
of recreational adult-use marijuana began (October
2020). In contrast, previous studies primarily
examined changes in hospitalization rates spanning
the period recreational adult-use went into effect.
For example, a study in Colorado found cannabisrelated hospitalizations (identified using diagnosis
codes in the top 3 positions) doubled from 274 to
593 per 100 000 hospitalizations between 2000
and 2015, after medical marijuana was legalized
(2000) and spanning the period recreational adultuse went into effect (2014).6 These data suggest
that cannabis-related hospitalization rates might
increase even further in Maine as recreational
adult-use marijuana takes effect after 2020.
We found increasing rates in cannabis-related
hospitalizations among both urban and rural
residents, though recent trends (2016 to 2020)
among rural residents were flat. These findings are
generally consistent with research showing that the
prevalence of cannabis use is increasing in both
rural and urban areas in the United States.11 No
previous study of cannabis-related hospitalization
rates around the time of recreational adult-use
legalization has reported hospitalization rates by
rurality of patient residence. The higher rates of
cannabis-related hospitalizations among urban vs

Published by MaineHealth Knowledge Connection, 2022

rural residents in Maine in recent years warrants
further study.
Regarding opioid-related hospitalizations, we
found increasing rates since 2016, particularly for
urban residents. Although states that legalized
medical marijuana have lower subsequent opioidrelated hospitalizations than states that have
not yet legalized medical marijuana, both types
of states have seen increases in opioid-related
hospitalizations over the past 2 decades.20 Trends
in opioid-related hospitalizations should continue to
be monitored to see if rates after recreational adultuse marijuana goes into effect in Maine are lower
than would be expected, as some studies suggest
might happen.20-22 As with cannabis, higher rates
of opioid-related hospitalizations among urban
residents deserve further scrutiny.
One of the strengths of our analysis is that we used
data on all inpatient encounters in Maine from the
state-wide census. We were able to accurately
group the encounters into urban and rural
residences based on zip code. By age-standardizing
hospitalization rates to the 2000 US population, we
can compare hospitalization rates in Maine to other
states with different age distributions, as well as
rates between urban and rural residents in Maine.
The primary limitation of our analysis is the
transition from ICD-9-CM to ICD-10-CM coding,
which prevented us from modeling trends in
hospitalization rates smoothly over the 11-year
study. Another limitation is the impact that the
COVID-19 pandemic had on health care use
during 2020. In the United States, hospitalization
admissions unrelated to COVID-19 reached a low of
roughly 64% of predicted admissions for April 2020.
By the end of 2020, admissions were approximately
80% of predicted admissions.39 In accordance, we
observed the total number of inpatient encounters
in Maine were lowest in 2020 across all study
years. Therefore, the number of cannabis-related
and opioid-related inpatient encounters may have
been even greater had there not been a pandemic.
A final limitation is that our analysis relied on
administrative billing codes, which can be imperfect
measures of cannabis-related and opioid-related
hospitalizations.
As recreational adult-use marijuana is fully
implemented in Maine, future research on public
health impacts can be informed by findings
9
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from Colorado, one of the first states to legalize
recreational adult-use marijuana. A recent study from
the Colorado Department of Public Safety found the
number of arrests for driving under the influence of
marijuana increased by 120% from 2014 to 2020,
and the number of marijuana exposure calls to poison
control centers increased by 573%.40 Another study in
Colorado suggests that the 29% increase in vomitingrelated encounters in the emergency department from
2013 to 2018 was due to legalization of recreational
adult-use marijuana in that state.41 Therefore, future
research in Maine should go beyond hospitalization
data to include a broader public health assessment
of the potential impacts of recreational adult-use
legalization.

CONCLUSIONS
In conclusion, our study showed increasing rates
of cannabis-related inpatient encounters in Maine,
spanning a period that includes when recreational
adult-use marijuana was legalized. Opioid-related
hospitalization rates also increased during this
period. These trends and other public health impacts
of increased access to marijuana use in Maine should
continue to be monitored, especially after recreational
adult-use marijuana is fully implemented.
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Appendix A. Code Lists
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Cannabis-related hospitalizations
ICD-9
304.30-304.33, Cannabis dependence
305.20-305.23, Cannabis abuse

ICD-10
F12, Mental and behavioral disorders due to use of cannabinoids
T40.7, Poisoning by, adverse effect of and underdosing by narcotics and psychodysleptics [hallucinogens] Cannabis (derivatives)

Opioid-related hospitalizations
ICD-9
304.00-304.03, Opioid dependence
304.70-304.73, Combinations of opioid type drug with any other dependence
305.50-305.53, Opioid abuse
965.0, Poisoning by opiates and related narcotics
970.1. Poisoning by opiate antagonists
E850.0, Accidental poisoning by heroin
E850.1, Accidental poisoning by methadone
E850.2, Accidental poisoning by other opiates and related narcotics
E935.0, Heroin causing adverse effects in therapeutic use
E935.1, Methadone causing adverse effects in therapeutic use
E935.2, Other opiates and related narcotics causing adverse effects in therapeutic use
E940.1, Opiate antagonists causing adverse effects in therapeutic use

ICD-10
F11, Mental and behavioral disorders due to use of opioids
T40.0, Poisoning by, adverse effect of and underdosing by narcotics and psychodysleptics: Opium
T40.1, Poisoning by, adverse effect of and underdosing by narcotics and psychodysleptics: Heroin
T40.2, Poisoning by, adverse effect of and underdosing by narcotics and psychodysleptics: Other opioids
T40.3, Poisoning by, adverse effect of and underdosing by narcotics and psychodysleptics: Methadone
T40.4, Poisoning by, adverse effect of and underdosing by narcotics and psychodysleptics: Other synthetic
narcotics
T40.6, Poisoning by, adverse effect of and underdosing by narcotics and psychodysleptics: Other and
unspecified narcotics

COVID-19 hospitalizations
ICD-10
U07.1, 2019-nCoV acute respiratory disease
Z11.52, Encounter for screening for COVID-19
Z20.822, Contact with and (suspected) exposure to COVID-19
Z86.16, Personal history of COVID-19
M35.81, Multisystem inflammatory syndrome (MIC)
M35.89, Other specified systemic involvement of connective tissue
J12.82, Pneumonia due to coronavirus disease

Neonatal hospitalizations
Version 26, 27, 28,29,30,31,32,33,34,35,36,37,37.1,37.2,38
MS-DRG 789,790,791,792,793,794,795

Maternal hospitalizations
Vaginal Delivery
Version 26,27,28,29,30,31,32,33,34,35
MS-DRG 767,768,774,775
Version 36,37,37.1,37.2,38
MS-DRG 768,796,797,798,805,806,807

C-Section
Version 26,27,28,29,30,31,32,33,34,35
MS-DRG 765,766

https://knowledgeconnection.mainehealth.org/jmmc/vol4/iss2/2
Version 36,37,37.1,37.2,38
DOI: 10.46804/2641-2225.1119
MS-DRG 783,784,785,786,787,788
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